Gameto, an Austin-based biotech company focused on women’s health, announced $44 million in Series C funding. Overwater Ventures led the round that brings Gameto’s total venture capital to $127 million.
Currently used in clinics across Peru, Mexico and Australia, Gameto’s lead program, Fertilo, is an induced pluripotent stem cell-derived therapy designed to mature egg cells outside of the body ahead of IVF. Fertilo does this using engineered ovarian support cells as a way to reduce the current ovarian stimulation protocol from two weeks of daily hormone injections to only two to three days.
The new capital will help Gameto complete the ongoing Phase 3 trial for Fertilo as the company works to evaluate the therapy’s safety and efficacy across up to 20 U.S. study sites.
